Skip to main content
. 2020 Apr 26;34(6):803–811. doi: 10.1177/0269215520911970

Figure 2.

Figure 2.

Change from baseline to Week 4 and Week 12 in (a) upper limb CXA, (b) lower limb CXA, (c) upper limb active function, and (d) lower limb active function, during the open-label extension studies.

CXA: composite active range of motion; MFS: Modified Frenchay Scale; n: number of patients with data at both Week 4 and Week 12 of each cycle.

Data are presented as mean [95% confidence interval]. Active function was assessed by the MFS (upper limb) and unaided comfortable barefoot walking speed (lower limb).